Breast Cancer | Specialty

Dr. Pegram on Challenges in Neoadjuvant Treatment for HER2-Positive Breast Cancer

February 28th 2015

Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, goes over some of the challenges surrounding neoadjuvant treatment for HER2-positive breast cancer patients.

Dr. Muss on Optimizing Adjuvant Treatment for Older Breast Cancer Patients

February 28th 2015

Hyman B. Muss, MD, professor of oncology, University of North Carolina, director, Geriatric Oncology, Lineberger Comprehensive Cancer Center, discusses optimizing adjuvant treatment in older patients with breast cancer.

Joan Lunden Paints a Picture of Breast Cancer From the Patient's Perspective

February 28th 2015

Joan Lunden presented the keynote address at the Miami Breast Cancer Conference where she spoke powerfully and from the heart in a talk perfectly aligned with the meeting's focus on the patient perspective.

Heterogeneity Complicates Treatment Decisions in Breast Cancer

February 28th 2015

Heterogeneity, which can result in treatment resistance, is commonly underestimated and misunderstood, representing an important area of future research.

Hudis Highlights Interplay Between Inflammation, Obesity, and Breast Cancer

February 28th 2015

In a discussion at the Miami Breast Cancer Conference, Clifford A. Hudis, MD, suggested that an increased risk for developing breast cancer might be a consequence of inflammation that often accompanies obesity.

Dr. Sledge on Using Tumor Heterogeneity to Guide Treatment in Breast Cancer

February 28th 2015

George W. Sledge, Jr., MD, professor of medicine, Stanford University School of Medicine, explains how tumor heterogeneity impacts patient care and research.

Dr. Carey on Treating Triple-Negative Breast Cancer

February 28th 2015

Lisa A. Carey, MD, professor of medicine, Breast Cancer Research, University of North Carolina, medical director, UNC Breast Center, chief of Hematology/Oncology, physician-in-chief, UNC North Carolina Cancer Hospital, discusses treatment options and challenges in triple-negative breast cancer.

Early Intervention Essential for Proper Lymphedema Management

February 27th 2015

Moving early to diagnose and treat lymphedema after breast cancer treatment can reverse this side effect or prevent it from becoming more severe.

Driver Mutations Remain Prognostic But Not Predictive in Breast Cancer

February 27th 2015

Tumor genome profiling identifies driver mutations in breast tumors, however, it is still too early to use this information in clinical decision making.

Neoadjuvant Endocrine Therapy Appropriate in Select Patients

February 27th 2015

While not appropriate for all patients with ER-positive breast cancer, neoadjuvant endocrine therapy could play an important role in select groups of women with comorbidities or those with ER-rich/luminal A disease.

Excitement Building for PARP Inhibitors in BRCA-Mutated Breast Cancer

February 27th 2015

The FDA's recent approval of the first PARP inhibitor suggests that this new class of targeted therapy has great potential to help not only patients with ovarian cancer for whom the agent is indicated but also individuals with breast cancer.

Dr. Tripathy on the Possibility of Curing Metastatic Breast Cancer

February 26th 2015

Debu Tripathy, MD, professor of medicine, chair, department of breast medical oncology, The University of Texas MD Anderson Cancer Center, discusses the possibility of one day being able to cure metastatic breast cancer.

Dr. Attai on What Physicians Can Learn from Social Media

February 26th 2015

Deanna J. Attai, MD, breast surgeon, assistant clinical professor of surgery, David Geffen School of Medicine, University of California, Los Angeles, explains how social media can help physicians.

MBCC Embraces Revolution in Breast Cancer Care

February 26th 2015

The landscape of breast cancer care is shifting rapidly, but that doesn't worry the organizers of the 32nd Annual Miami Breast Cancer Conference.

Three Experts Examine the ER-Positive Treatment Landscape

February 26th 2015

With the evolution of treatment under way, OncLive interviewed three world-renowned experts in the field: Joanne L. Blum, MD, PhD, Adam M. Brufsky, MD, PhD, and Harold J. Burstein, MD, PhD.

Future Treatments for Triple-Negative Breast Cancer

February 25th 2015

Chemotherapeutics for Triple-Negative Breast Cancer

February 25th 2015

Standard Therapies for Triple-Negative Breast Cancer

February 25th 2015

Managing Brain Metastases in Breast Cancer

February 25th 2015

Role of T-DM1 in HER2-Positive Breast Cancer

February 25th 2015